New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress

Figures

• 

  Figure 1. (A–D). Between-groups analysis of IL-6 (A), creatinine (B), urea (C) levels, and platelet count (D), after ANOVA results (see Table 2) in hospitalized COVID-19 patients with new-onset atrial fibrillation (new-onset AF, n = 25, black column), with other forms of AF (other AF, n = 22, dark grey column) and without AF (no AF, n = 128, light grey column). Data are expressed as median ± interquartile range. * = p < 0.5; ns = not significant.

• 

  Figure 2. (A–C). Associations between IL-6 and kidney function (creatinine and urea, A,B) and platelet count (C) in hospitalized COVID-19 patients with new-onset atrial fibrillation (new-onset AF, n = 25).

• 

  Figure 3. (A–C). Kaplan-Meier survival plot analysis for hospitalized COVID-19 patients, after the exclusion of participants with PaO2/FiO2 > 300, with new-onset atrial fibrillation (new-onset AF, n = 19, red line), with other forms of AF (other AF, n = 18, blue line) and without AF (no AF, n = 103, green line) at 28 days (A) and at 5 days (B). Interleukin 6 (IL-6) serum levels comparison between study groups (C), after the exclusion of participants with PaO2/FiO2 > 300. Data are expressed as median ± interquartile range. *** = p < 0.0005.

• 

  Figure 4. (A–D). Kaplan-Meier survival plot analysis for hospitalized COVID-19 patients with new-onset atrial fibrillation (new-onset AF, n = 25, red line), with other forms of AF (other AF, n = 22, blue line) and without AF (no AF, n = 128, green line) at 28 days (A) and at 5 days (C). Cox regression analysis results show that IL-6, creatinine, new-onset atrial fibrillation and PaO2/FiO2 < 300 are independent predictors of 28-days (B) and 5 days mortality (D).